Boston Scientific is reaping the rewards from the energised PFA market opportunity in atrial fibrillation treatment.

Farapulse, Boston Scientific’s pulsed field ablation product, fueled year-over-year growth of nearly 171% in the fourth ...

as the narrow-moat-rated Boston Scientific largely met our full-year expectations, and our 2025 projections remain bounded by management's outlook. We expect the Farapulse franchise for atrial ...

Boston Scientific apparently knows a good bet when it sees one. | That includes treating more than 200,000 patients with the irregular heartbeat known as atrial fibrillation—and the sum more than ...

CEO Michael Mahoney highlighted the company’s exceptional performance in 2024, with operational sales growth of 23% in Q4 and 18.5% for the full year. Organic sales grew 20% in Q4, exceeding guidance.

We recently compiled a list of the 10 Best Momentum Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Boston Scientific Corporation (NYSE:BSX), a leading player in the medical technology sector, has been making waves in the industry with its innovative product pipeline and strong market performance.

Potential supply chain challenges were addressed, with management affirming adequate capacity to meet growing FARAPULSE demand. Boston Scientific delivered another strong quarter, exceeding ...

Boston Scientific (NYSE: BSX) shares ticked up slightly before hours today on fourth-quarter results that beat the consensus ...